Brief: Vincerx Pharma Announces First Patient Dosed In Phase 1 Dose-Escalation Study Of VIP152 In Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Richter Syndrome
17/12/2021 13:12
Dec 17 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
DOSE-ESCALATION STUDY OF VIP152 IN RELAPSED OR REFRACTORY
CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER SYNDROME
Source text for Eikon: ID:nGNX5vw0X0
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign